AIM ImmunoTech Inc.
For the period ended Sep 30, 2025. Filed Nov 17, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description |
| 3.1(i) | Certificate of Incorporation as Amended and Restated through the date hereof (incorporated by reference to Exhibit 3.1 (1) to the Company’s Current report on Form 8-K (No. 001-27027) filed October 29, 2025). |
| 3.1(ii) | Amended and Restated By-Laws (incorporated by reference to Exhibit 3.7(ii) to the Company’s Current report on Form 8-K (No. 001-27072) filed February 26, 2025). |
| 10.1 | April 1, 2025 Equity Distribution Agreement with Maxim (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-3 (No. 333-286319) filed on April 1, 2025). |
| 10.2 | April 1, 2025 Agreement between the Company and Messrs. Equels and Rodino (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (No. 001-27072) for period ended June 30, 2025). |
| 10.3 | October 16, 2025 Lease extension for Riverton office* |
| 31.1 | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer. * |
| 31.2 | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer. * |
| 32.1 | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer. * |
| 32.2 | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer. * |
| 101.INS | Inline XBRL Instance Document |
| 101.SCH | Inline XBRL Taxonomy Schema |
| 101.CAL | Inline XBRL Taxonomy Calculation Linkbase |
| 101.DEF | Inline XBRL Taxonomy Definition Linkbase |
| 101.LAB | Inline XBRL Taxonomy Label Linkbase |
| 101.PRE | Inline XBRL Taxonomy Presentation Linkbase |
| 104 | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit) |
| * | Filed herewith. |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AIM IMMUNOTECH INC.
/s/ Thomas K. Equels
Thomas K. Equels, Esq.
Chief Executive Officer & President
/s/ Robert Dickey IV
Robert Dickey IV
Chief Financial Officer
Date: November 15, 2025
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.